COVID-19

Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

First digital-droplet PCR assay to receive coverageExpect initial revenue generation in Q1 2024IRVINE, CA / ACCESSWIRE / August 28, 2023…

10 months ago

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years

Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol…

10 months ago

Rhythm Pharmaceuticals to Present at Investor Conferences in September

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

10 months ago

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed…

10 months ago

Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium

ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an…

10 months ago

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model

Treatment with GT-02287 also restored glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, increased dopamine levels and…

10 months ago

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.1%

BAUDETTE, Minn., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that…

10 months ago

CloudMD Reports Second Quarter 2023 CloudMD Continues to Drive Execution with Adjusted EBITDA Approaching Breakeven

Adjusted EBITDA1 loss of $0.7 million. This was CloudMD’s third consecutive quarter of improving Adjusted EBITDA, representing a $2.5 million…

10 months ago

Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio

Sandoz completes acquisition of worldwide brand rights for Mycamine®(micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes,…

10 months ago